Good MorningThe S&P 500 and Dow Jones Industrial Average snapped three-day winning streaks on Tuesday putting an early end to the Santa Claus Rally. The decline comes just a day after the indices set new all-time highs and may lead to a deeper decline on Wednesday. There is growing evidence of weakness within the market that has it set up to fall 2-3% over the coming days.
The signs of weakness include tepid volume and divergences in both the MACD and stochastic indicators. Divergences are important signals for traders and investors to watch for. A divergence happens when a stock, index, or commodity moves to set a new high or a new low, and the indicators fail to match it. The caveat is that divergences do not always lead to market declines, at least not deep ones. With the market in an uptrend, it is possible a 2% to 3% decline will result in another buying opportunity.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Markets | | LIDAR technology company Velodyne Lidar, Inc. (NASDAQ: VLDR) stock has been a rollercoaster after its SPAC reverse merger on Sept. 29, 2020. The premier maker of light detection and ranging (LIDAR) sensor systems has seen a momentum surge in the segment as sentiment for autonomous vehicles improved.... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | | Information technology infrastructure company SolarWinds Corporation (NYSE: SWI) stock has been punished heavily from security and breaches on its Orion platform linked to Russian hacker groups. Shares have collapsed more than (-30%) since the first report on Dec. 13, 2020. Shares are down (-15%) mi... Read the Full Story |
|
Industrials | | A Long Road For Boeing
Boeing (NYSE:BA) is going on watch today as it’s best-selling plane returns to the skies. The first commercial flight in the U.S. resumed today with flights from American Airlines. The first flight is between New York and Miami with the return flight projected to be ful... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Consumer Discretionary | | Having watched their shares fall 90% in the six years prior to 2020, and then watching them slip under the $3 mark in April, investors in GameStop (NYSE: GME) must have surely been expecting to see their stock trade at $0.20 before it traded at $20 again.
But the stock market works in mysterious wa... Read the Full Story |
|
Healthcare | | Dividend-Growth Is On The Table In 2021
While the average market participant may sit back wondering whether dividends or growth is the better position for 2021 there is a third choice that investors should consider. Dividend-Growth stocks. Dividend-Growth stocks offer the best of both worlds by co... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Technology | |
While the S&P 500 up about 14% year-to-date, there have been some standout performers. Including the newly added Tesla, nine of the index's components have at least doubled so far this year. Some may have peaked for the moment, but others appear to have plenty more room to run. Here we review ... Read the Full Story |
|
Markets | | Satellite TV, wireless, and broadband provider DISH Network Corporation (NASDAQ: DISH) stock has been punished in December trading down (-13%) year-to-date (YTD) versus the 14% YTD performance of the benchmark S&P 500 index (NYSEARCA: SPY). Shares were punished when the Company priced a $2 billi... Read the Full Story |
|
Healthcare | | Clinical stage biotechnology company Moderna, Inc. (NASDAQ: MRNA) stock has been in the forefront during the pandemic in the battle against COVID-19. Shares are still up over 500% year-to-date (YTD) as vaccine approval and distribution is well underway. While shares have peaked at $178.50, the sell-... Read the Full Story |
|
Healthcare | |
When you start to think about all of the different applications for cloud software in the world, it’s easy to see why investors have been scooping up shares of companies in the sector. Cloud computing helps companies achieve better business efficiencies, more flexibility, cost savings, incre... Read the Full Story |
|
Consumer Discretionary | |
Back in August, Beazer Homes (NYSE: BZH) staged a powerful breakout, with the move coming on high volume and the closing price right around the day’s highs.
After slowly, but steadily increasing for much of the fall, Beazer formed a four-week base between mid-November and mid-December. On T... Read the Full Story |
|
The Early Bird Stock Of The Day Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
